Editas Medicine (EDIT) Cash from Operations Growth (3y) (2018 - 2025)

Editas Medicine (EDIT) Cash from Operations Growth (3y) (2018 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -5.07%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 33.08%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -7.60%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Editas Medicine 245.95 Mn 99.30 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 13.71%
Jun 30, 2025 -9.88%
Mar 31, 2025 0.98%
Dec 31, 2024 -13.65%
Sep 30, 2024 -8.84%
Jun 30, 2024 -13.57%
Mar 31, 2024 -0.26%
Dec 31, 2023 17.84%
Sep 30, 2023 13.51%
Jun 30, 2023 -7.85%
Mar 31, 2023 12.88%
Dec 31, 2022 -44.71%
Sep 30, 2022 -21.32%
Jun 30, 2022 -13.61%
Mar 31, 2022 -19.29%
Dec 31, 2021 -203.88%
Sep 30, 2021 -73.26%
Jun 30, 2021 -32.54%
Mar 31, 2021 -30.12%
Sep 30, 2020 -76.53%